NNV1 is under clinical development by TheraBiologics and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase I drugs for High-Grade Glioma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the NNV1 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NNV1 is under development for the treatment of recurrent glioblastoma multiforme (GBM), anaplastic astrocytoma, gliosarcoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma and high-grade glioma. The therapeutic candidate comprises immortalized neural stem cells (NSC) loaded with oncolytic adenovirus (CRAd-S-pk7). It is administered through intracerebral route and is being developed based on NeuroNova platform.
It was also under development for the treatment of malignant glioma.
TheraBiologics (TBX) is a clinical-stage bio pharmaceutical company which develops human neural stem cell (NSC)-mediated cancer therapies. It lead product candidates include TBX.OncV, a cancer gene therapy product which produce oncolytic adenovirus targeting multiple heterogeneous tumors, that replicate tumor cells, and does not affect normal cells; TBX.CE, an enzyme or prodrug gene therapy product that activates the prodrug irinotecan to chemotherapeutic drug against metastatic neuroblastoma. The company’s TBX NSC platform is engineered to deliver a range of anti-cancer agents targeting invasive cancers which enable to maximize therapeutic concentrations at the tumor sites and minimize off target toxicities. TBX is headquartered in Arcadia, California, the US.
For a complete picture of NNV1’s drug-specific PTSR and LoA scores, buy the report here.